O	0	1	N	N	NN	B-NP
O	1	2	-	-	HYPH	I-NP
O	2	15	glycosylation	glycosylation	NN	I-NP
O	16	18	of	of	IN	B-PP
O	19	26	glucose	glucose	NN	B-NP
O	27	38	transporter	transporter	NN	I-NP
O	38	39	-	-	HYPH	B-NP
O	39	40	1	1	CD	I-NP
O	41	42	(	(	(	O
O	42	46	Glut	Glut	NN	B-NP
O	46	47	-	-	HYPH	B-NP
O	47	48	1	1	CD	I-NP
O	48	49	)	)	)	O
O	50	52	is	be	VBZ	B-VP
O	53	63	associated	associate	VBN	I-VP
O	64	68	with	with	IN	B-PP
O	69	78	increased	increase	VBN	B-NP
O	79	90	transporter	transporter	NN	I-NP
O	91	99	affinity	affinity	NN	I-NP
O	100	103	for	for	IN	B-PP
O	104	111	glucose	glucose	NN	B-NP
O	112	114	in	in	IN	B-PP
O	115	120	human	human	JJ	B-NP
B-Cell	121	129	leukemic	leukemic	JJ	I-NP
I-Cell	130	135	cells	cell	NNS	I-NP
O	135	136	.	.	.	O

O	137	139	To	To	TO	B-VP
O	140	149	elucidate	elucidate	VB	I-VP
O	150	153	the	the	DT	B-NP
O	154	158	role	role	NN	I-NP
O	159	161	of	of	IN	B-PP
O	162	163	N	N	NN	B-NP
O	163	164	-	-	HYPH	B-NP
O	164	177	glycosylation	glycosylation	NN	I-NP
O	178	180	in	in	IN	B-PP
O	181	184	the	the	DT	B-NP
O	185	195	functional	functional	JJ	I-NP
O	196	204	activity	activity	NN	I-NP
O	205	207	of	of	IN	B-PP
O	208	211	the	the	DT	B-NP
O	212	221	universal	universal	JJ	I-NP
O	222	229	glucose	glucose	NN	I-NP
O	230	241	transporter	transporter	NN	I-NP
O	241	242	,	,	,	O
O	243	247	Glut	Glut	NN	B-NP
O	247	248	-	-	HYPH	B-NP
O	248	249	1	1	CD	I-NP
O	249	250	,	,	,	O
O	251	253	we	we	PRP	B-NP
O	254	266	investigated	investigate	VBD	B-VP
O	267	274	effects	effect	NNS	B-NP
O	275	277	of	of	IN	B-PP
O	278	281	the	the	DT	B-NP
O	282	283	N	N	NN	I-NP
O	283	284	-	-	HYPH	B-NP
O	284	297	glycosylation	glycosylation	NN	I-NP
O	298	307	inhibitor	inhibitor	NN	I-NP
O	307	308	,	,	,	O
O	309	320	tunicamycin	tunicamycin	NN	B-NP
O	320	321	,	,	,	O
O	322	324	on	on	IN	B-PP
O	325	332	glucose	glucose	NN	B-NP
O	333	342	transport	transport	NN	I-NP
O	343	345	by	by	IN	B-PP
O	346	351	human	human	JJ	B-NP
B-Cell	352	360	leukemic	leukemic	JJ	I-NP
I-Cell	361	365	cell	cell	NN	I-NP
I-Cell	366	371	lines	line	NNS	I-NP
I-Cell	372	376	K562	K562	NN	I-NP
O	376	377	,	,	,	I-NP
B-Cell	378	382	U937	U937	NN	I-NP
O	383	386	and	and	CC	I-NP
B-Cell	387	391	HL60	HL60	NN	I-NP
O	391	392	.	.	.	O

O	393	402	Treatment	Treatment	NN	B-NP
O	403	407	with	with	IN	B-PP
O	408	419	tunicamycin	tunicamycin	NN	B-NP
O	420	428	produced	produce	VBD	B-VP
O	429	430	a	a	DT	B-NP
O	431	433	40	40	CD	I-NP
O	433	434	-	-	HYPH	I-NP
O	434	436	50	50	CD	I-NP
O	436	437	%	%	NN	I-NP
O	438	448	inhibition	inhibition	NN	I-NP
O	449	451	of	of	IN	B-PP
O	452	453	2	2	CD	B-NP
O	453	454	-	-	HYPH	I-NP
O	454	466	deoxyglucose	deoxyglucose	NN	I-NP
O	467	473	uptake	uptake	NN	I-NP
O	474	477	and	and	CC	O
O	478	482	this	this	DT	B-NP
O	483	486	was	be	VBD	B-VP
O	487	497	associated	associate	VBN	I-VP
O	498	502	with	with	IN	B-PP
O	503	504	a	a	DT	B-NP
O	505	506	2	2	CD	I-NP
O	506	507	-	-	HYPH	I-NP
O	507	508	2	2	CD	I-NP
O	508	509	.	.	SYM	I-NP
O	509	510	5	5	CD	I-NP
O	510	511	-	-	HYPH	I-NP
O	511	515	fold	fold	JJ	I-NP
O	516	524	decrease	decrease	NN	I-NP
O	525	527	in	in	IN	B-PP
O	528	539	transporter	transporter	NN	B-NP
O	540	548	affinity	affinity	NN	I-NP
O	549	552	for	for	IN	B-PP
O	553	560	glucose	glucose	NN	B-NP
O	561	562	(	(	(	O
O	562	564	Km	Km	NN	B-NP
O	564	565	)	)	)	O
O	566	573	without	without	IN	B-PP
O	574	575	a	a	DT	B-NP
O	576	582	change	change	NN	I-NP
O	583	585	in	in	IN	B-PP
O	586	590	Vmax	Vmax	NN	B-NP
O	590	591	.	.	.	O

B-Cell	592	600	Leukemic	Leukemic	JJ	B-NP
I-Cell	601	605	K562	K562	NN	I-NP
O	605	606	,	,	,	I-NP
B-Cell	607	611	U937	U937	NN	I-NP
O	612	615	and	and	CC	I-NP
B-Cell	616	620	HL60	HL60	NN	I-NP
I-Cell	621	626	cells	cell	NNS	I-NP
O	627	636	expressed	express	VBD	B-VP
O	637	641	Glut	Glut	NN	B-NP
O	641	642	-	-	HYPH	B-NP
O	642	643	1	1	CD	I-NP
O	644	655	transporter	transporter	NN	I-NP
O	656	663	protein	protein	NN	I-NP
O	663	664	.	.	.	O

O	665	669	With	With	IN	B-PP
B-Cell	670	674	K562	K562	NN	B-NP
I-Cell	675	680	cells	cell	NNS	I-NP
O	681	685	Glut	Glut	NN	I-NP
O	685	686	-	-	HYPH	B-NP
O	686	687	1	1	CD	I-NP
O	688	696	appeared	appear	VBD	B-VP
O	697	699	as	as	IN	B-PP
O	700	701	a	a	DT	B-NP
O	702	707	broad	broad	JJ	I-NP
O	708	712	band	band	NN	I-NP
O	713	715	of	of	IN	B-PP
O	716	718	50	50	CD	B-NP
O	718	719	-	-	HYPH	I-NP
O	719	721	60	60	CD	I-NP
O	722	725	kDa	kDa	NN	I-NP
O	725	726	,	,	,	O
O	727	734	whereas	whereas	IN	O
O	735	739	with	with	IN	B-PP
B-Cell	740	744	U937	U937	NN	B-NP
O	745	748	and	and	CC	I-NP
B-Cell	749	753	HL60	HL60	NN	I-NP
I-Cell	754	759	cells	cell	NNS	I-NP
O	760	761	a	a	DT	B-NP
O	762	769	diffuse	diffuse	JJ	I-NP
O	770	774	band	band	NN	I-NP
O	775	778	was	be	VBD	B-VP
O	779	787	observed	observe	VBN	I-VP
O	788	790	at	at	IN	B-PP
O	791	804	approximately	approximately	RB	B-NP
O	805	807	55	55	CD	I-NP
O	808	811	kDa	kDa	NN	I-NP
O	811	812	.	.	.	O

O	813	822	Treatment	Treatment	NN	B-NP
O	823	825	of	of	IN	B-PP
B-Cell	826	830	K562	K562	NN	B-NP
I-Cell	831	836	cells	cell	NNS	I-NP
O	837	841	with	with	IN	B-PP
O	842	853	tunicamycin	tunicamycin	NN	B-NP
O	854	857	for	for	IN	B-PP
O	858	860	18	18	CD	B-NP
O	861	862	h	h	NN	I-NP
O	862	863	,	,	,	O
O	864	872	resulted	result	VBD	B-VP
O	873	875	in	in	IN	B-PP
O	876	885	extensive	extensive	JJ	B-NP
O	886	890	loss	loss	NN	I-NP
O	891	893	of	of	IN	B-PP
O	894	897	the	the	DT	B-NP
O	898	900	50	50	CD	I-NP
O	900	901	-	-	HYPH	I-NP
O	901	903	60	60	CD	I-NP
O	904	907	kDa	kDa	NN	I-NP
O	908	920	glycoprotein	glycoprotein	NN	I-NP
O	920	921	,	,	,	O
O	922	932	appearance	appearance	NN	B-NP
O	933	935	of	of	IN	B-PP
O	936	937	a	a	DT	B-NP
O	938	940	30	30	CD	I-NP
O	940	941	-	-	HYPH	I-NP
O	941	943	40	40	CD	I-NP
O	944	947	kDa	kDa	NN	I-NP
O	948	952	band	band	NN	I-NP
O	953	956	and	and	CC	O
O	957	966	increased	increase	VBN	B-NP
O	967	975	staining	staining	NN	I-NP
O	976	978	of	of	IN	B-PP
O	979	980	a	a	DT	B-NP
O	981	983	45	45	CD	I-NP
O	984	987	kDa	kDa	NN	I-NP
O	988	992	band	band	NN	I-NP
O	992	993	.	.	.	O

O	994	998	With	With	IN	B-PP
B-Cell	999	1003	U937	U937	NN	B-NP
I-Cell	1004	1009	cells	cell	NNS	I-NP
O	1009	1010	,	,	,	O
O	1011	1022	tunicamycin	tunicamycin	NN	B-NP
O	1023	1032	treatment	treatment	NN	I-NP
O	1033	1041	resulted	result	VBD	B-VP
O	1042	1044	in	in	IN	B-PP
O	1045	1048	the	the	DT	B-NP
O	1049	1059	appearance	appearance	NN	I-NP
O	1060	1062	of	of	IN	B-PP
O	1063	1064	a	a	DT	B-NP
O	1065	1067	30	30	CD	I-NP
O	1067	1068	-	-	HYPH	I-NP
O	1068	1070	40	40	CD	I-NP
O	1071	1074	kDa	kDa	NN	I-NP
O	1075	1079	band	band	NN	I-NP
O	1080	1083	and	and	CC	O
O	1084	1093	increased	increase	VBN	B-NP
O	1094	1102	staining	staining	NN	I-NP
O	1103	1105	of	of	IN	B-PP
O	1106	1107	a	a	DT	B-NP
O	1108	1110	45	45	CD	I-NP
O	1111	1114	kDa	kDa	NN	I-NP
O	1115	1119	band	band	NN	I-NP
O	1119	1120	.	.	.	O

O	1121	1125	With	With	IN	B-PP
B-Cell	1126	1130	HL60	HL60	NN	B-NP
I-Cell	1131	1136	cells	cell	NNS	I-NP
O	1137	1141	loss	loss	NN	I-NP
O	1142	1144	of	of	IN	B-PP
O	1145	1148	the	the	DT	B-NP
O	1149	1151	55	55	CD	I-NP
O	1152	1155	kDa	kDa	NN	I-NP
O	1156	1160	Glut	Glut	NN	I-NP
O	1160	1161	-	-	HYPH	B-NP
O	1161	1162	1	1	CD	I-NP
O	1163	1167	band	band	NN	I-NP
O	1168	1171	was	be	VBD	B-VP
O	1172	1180	observed	observe	VBN	I-VP
O	1181	1184	and	and	CC	O
O	1185	1186	a	a	DT	B-NP
O	1187	1191	band	band	NN	I-NP
O	1192	1194	of	of	IN	B-PP
O	1195	1197	45	45	CD	B-NP
O	1198	1201	kDa	kDa	NN	I-NP
O	1202	1210	appeared	appear	VBD	B-VP
O	1210	1211	.	.	.	O

O	1212	1223	Tunicamycin	Tunicamycin	NN	B-NP
O	1223	1224	-	-	HYPH	I-NP
O	1224	1233	treatment	treatment	NN	I-NP
O	1234	1242	resulted	result	VBD	B-VP
O	1243	1245	in	in	IN	B-PP
O	1246	1248	75	75	CD	B-NP
O	1248	1249	-	-	HYPH	I-NP
O	1249	1251	90	90	CD	I-NP
O	1251	1252	%	%	NN	I-NP
O	1253	1263	inhibition	inhibition	NN	I-NP
O	1264	1266	in	in	IN	B-PP
O	1267	1268	[	[	(	B-NP
O	1268	1270	3H	3H	NN	I-NP
O	1270	1271	]	]	)	I-NP
O	1271	1278	mannose	mannose	NN	I-NP
O	1279	1292	incorporation	incorporation	NN	I-NP
O	1293	1296	but	but	CC	O
O	1297	1301	only	only	RB	B-NP
O	1302	1304	20	20	CD	I-NP
O	1304	1305	-	-	HYPH	I-NP
O	1305	1307	25	25	CD	I-NP
O	1307	1308	%	%	NN	I-NP
O	1309	1319	inhibition	inhibition	NN	I-NP
O	1320	1322	in	in	IN	B-PP
O	1323	1324	[	[	(	B-NP
O	1324	1326	3H	3H	NN	I-NP
O	1326	1327	]	]	)	I-NP
O	1327	1336	thymidine	thymidine	NN	I-NP
O	1337	1340	and	and	CC	O
O	1341	1342	[	[	(	B-NP
O	1342	1344	3H	3H	NN	I-NP
O	1344	1345	]	]	)	I-NP
O	1345	1352	leucine	leucine	NN	I-NP
O	1353	1366	incorporation	incorporation	NN	I-NP
O	1366	1367	.	.	.	O

O	1368	1370	In	In	IN	B-PP
O	1371	1379	contrast	contrast	NN	B-NP
O	1379	1380	,	,	,	O
O	1381	1392	tunicamycin	tunicamycin	NN	B-NP
O	1393	1396	had	have	VBD	B-VP
O	1397	1403	little	little	JJ	B-NP
O	1404	1410	effect	effect	NN	I-NP
O	1411	1413	on	on	IN	B-PP
O	1414	1417	the	the	DT	B-NP
O	1418	1427	viability	viability	NN	I-NP
O	1428	1431	and	and	CC	I-NP
O	1432	1435	MTT	MTT	NN	I-NP
O	1436	1445	responses	response	NNS	I-NP
O	1446	1448	of	of	IN	B-PP
O	1449	1452	the	the	DT	B-NP
B-Cell	1453	1458	cells	cell	NNS	I-NP
O	1459	1463	used	use	VBN	B-VP
O	1463	1464	.	.	.	O

O	1465	1470	These	These	DT	B-NP
O	1471	1478	results	result	NNS	I-NP
O	1479	1486	suggest	suggest	VBP	B-VP
O	1487	1491	that	that	IN	B-SBAR
O	1492	1494	in	in	IN	B-PP
B-Cell	1495	1503	leukemic	leukemic	JJ	B-NP
I-Cell	1504	1509	cells	cell	NNS	I-NP
O	1510	1511	N	N	NN	I-NP
O	1511	1512	-	-	HYPH	B-NP
O	1512	1525	glycosylation	glycosylation	NN	I-NP
O	1526	1528	of	of	IN	B-PP
O	1529	1533	Glut	Glut	NN	B-NP
O	1533	1534	-	-	HYPH	B-NP
O	1534	1535	1	1	CD	I-NP
O	1536	1541	plays	play	VBZ	B-VP
O	1542	1544	an	an	DT	B-NP
O	1545	1554	important	important	JJ	I-NP
O	1555	1559	role	role	NN	I-NP
O	1560	1562	in	in	IN	B-PP
O	1563	1574	maintaining	maintain	VBG	B-VP
O	1575	1578	its	its	PRP$	B-NP
O	1579	1588	structure	structure	NN	I-NP
O	1589	1592	and	and	CC	I-NP
O	1593	1603	functional	functional	JJ	I-NP
O	1604	1615	integration	integration	NN	I-NP
O	1615	1616	.	.	.	O

